Grant will fund partnership between Desktop Genetics and Imperial College London to develop and validate software tools to design and test site-specific epigenetic CRISPR systems to target drug resistance mechanisms in cancer cells.
London UK, 22nd February 2016: Desktop Genetics Ltd., a software company revolutionizing the way researchers use CRISPR genome editing technology, announced today that it has, in partnership with the Epigenetics Unit in the Division of Cancer at Imperial College London, received a grant for £300,000 ($430,000) from Innovate UK. Desktop Genetics will use the funds to develop software tools that selectively design CRISPR/Cas9 targets against cancer cell lines that are characterized at the epigenetic level, with the objective of improving chemotherapy and overcoming drug resistance. Professor Bob Brown, who leads the Epigenetics Unit of Imperial College London, will use this novel approach to investigate the epigenetic mechanisms underpinning resistance to chemotherapy in ovarian cancer cell lines.
The CRISPR software tools that Desktop Genetics will develop as a result of this project, aim to combine data-driven, intelligent, predictive biomodelling capabilities with the analysis of heterogeneous genomic and epigenomic data. The novel approach taken by Desktop Genetics will be to translate omics-based information, such as whole genomic, epigenomic and transcriptomic datasets, into precise CRISPR targets. The Epigenetics Unit will provide biological evidence that this model-driven tool can be used to identify, target and functionally study DNA regions that are critical to cancer progression and drug resistance in ovarian cancer cells. Given the key role of epigenetics in all tumor types, this research has wide potential applications across all types of cancer.
Leigh Brody, PhD, Director of Genomic Services at Desktop Genetics, commented: “There has been a great deal of excitement over the potential to use CRISPR in the clinic. We hope that an integrated omics approach to epigenetic CRISPR will support target validation of small-molecule therapies modifying the epigenetic landscape.”
Professor Brown, Chair of Translational Oncology in the Department of Surgery and Cancer at Imperial College London commented: “This project will combine the best elements of epigenetic research, bioinformatics and CRISPR to create a tool that solves a real problem in the field of oncology. We have recently shown specific epigenetic differences in ovarian tumors that respond poorly to treatment compared to those that do respond [1]. The approach of epigenetic editing using CRISPR can potentially target precise epigenetic changes in a personalized manner to specific genes to make tumor cells more sensitive to chemotherapy drugs. Such targeting will avoid some of the non-specific side effects in cancer and normal cells caused by current epigenetic therapies.”
The funded project is entitled Finding value in complex biological data – integrated omics collaborative R&D.
Media Contacts
Lorna Cuddon, Zyme Communications
lorna.cuddon@zymecommunications.com
Tel: +44 (0)7811 996 942
At Desktop Genetics:
Victor B Dillard, COO and Founder
victord@desktopgenetics.com
Tel: +44 (0)7891 633 808
About Desktop Genetics, Ltd www.deskgen.com
Desktop Genetics is a bioinformatics company specialising in gene editing tools and services. The company has developed the DESKGEN platform, an intuitive and powerful system that supports the optimal design, construction, management, and purchase of the DNA, reagents and services important in gene editing and molecular biology. The company offers state-of-the-art CRISPR library design services, and can coordinate DNA synthesis, library assembly, cell line engineering projects and high-throughput gene editing experiments for its customers. Desktop Genetics is an Illumina-backed company and works with recognized leaders in the gene editing field, including Editas Medicine, Horizon Discovery, and enEvolv. About the Epigenetics Unit, Imperial College London
Professor Brown heads the Imperial College London Epigenetics Unit and is Head of the Division of Cancer, in addition to the Chair in Translational Oncology in the Department of Surgery and Cancer within the Faculty of Medicine. He holds a joint appointment between Imperial College London and Institute of Cancer Research where he is Professor of Translational Oncology in the Section of Medicine. Professor Brown is Principal Investigator of a Cancer Research UK (CRUK) research programme, Drug Resistance and Epigenetics, Investigator in the Ovarian Cancer Action Research Centre and co-Principal Investigator at the CRUK/NIHR Experimental Cancer Medicine Centre.
About Innovate UK www.innovateuk.gov.uk
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.
References
1: Bonito NA,et al. Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer. Clin Cancer Res. 2016 Jan 13. PubMed PMID: 26763252.
Note to editors
Epigenetic changes to the genome, such as methylation or histone acetylation, can vary from cell to cell and are influenced, among other factors, by age, developmental stage and the environment. By regulating gene expression, epigenetic modifications appear to play a critical role in complex diseases such as cancer and diabetes.
